Haiying Xu

23.8k total citations · 3 hit papers
49 papers, 8.1k citations indexed

About

Haiying Xu is a scholar working on Oncology, Immunology and Surgery. According to data from OpenAlex, Haiying Xu has authored 49 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 27 papers in Immunology and 9 papers in Surgery. Recurrent topics in Haiying Xu's work include Immunotherapy and Immune Responses (22 papers), Cancer Immunotherapy and Biomarkers (22 papers) and CAR-T cell therapy research (11 papers). Haiying Xu is often cited by papers focused on Immunotherapy and Immune Responses (22 papers), Cancer Immunotherapy and Biomarkers (22 papers) and CAR-T cell therapy research (11 papers). Haiying Xu collaborates with scholars based in United States, China and Australia. Haiying Xu's co-authors include Janis M. Taube, Lieping Chen, Robert A. Anders, Drew M. Pardoll, Suzanne L. Topalian, Julie R. Brahmer, Jung Ho Kim, Alison Klein, Xiaoyu Pan and Rajni Sharma and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Haiying Xu

49 papers receiving 8.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

2014 1.9k citations Janis M. Taube, Alison Klein et al. Clinical Cancer Research profile →
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

2012 1.7k citations Janis M. Taube, Robert A. Anders et al. profile →
Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

2015 643 citations Kristin J. Lastwika, Willie Wilson et al. Cancer Research profile →

Peers

Countries citing papers authored by Haiying Xu

Since Specialization

Citations

This map shows the geographic impact of Haiying Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haiying Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haiying Xu more than expected).

Fields of papers citing papers by Haiying Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haiying Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haiying Xu. The network helps show where Haiying Xu may publish in the future.

Co-authorship network of co-authors of Haiying Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Haiying Xu. A scholar is included among the top collaborators of Haiying Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haiying Xu. Haiying Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Whole-Slide Imaging, Mutual Information Registration for Multiplex Immunohistochemistry and Immunofluorescence	Laboratory Investigation	Benjamin Green, Margaret Eminizer et al.	4
2	CD30 Lateral Flow and Enzyme-Linked Immunosorbent Assays for Detection of BIA-ALCL: A Pilot Study	Cancers	Haiying Xu, Jason T. Machan et al.	1
3	Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery	Cancer Immunology Research	Nicolás A. Giraldo, Sneha Berry et al.	6
4	PD-L1 expression in inflammatory myofibroblastic tumors	Modern Pathology	Tricia R. Cottrell, Christopher D. Gocke et al.	16
5	PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison	Clinical Cancer Research	Joel Sunshine, Peter Nguyen et al.	109
6	Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade	Journal for ImmunoTherapy of Cancer	Evan J. Lipson, Mohammed Lilo et al.	115
7	PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast	Modern Pathology	Elizabeth D. Thompson, Janis M. Taube et al.	36
8	Melanoma subtypes demonstrate distinct PD-L1 expression profiles	Laboratory Investigation	Genevieve J. Kaunitz, Tricia R. Cottrell et al.	157
9	The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma	Cancer Immunology Research	Maria Libera Ascierto, Tracee L. McMiller et al.	133
10	Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma	Aesthetic Surgery Journal	Marshall E. Kadin, Anand K. Deva et al.	115
11	Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer breakdown →	Cancer Research	Kristin J. Lastwika, Willie Wilson et al.	643
12	Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade	Clinical Cancer Research	Janis M. Taube, Geoffrey D. Young et al.	196
13	B7-H3 Promotes Pathogenesis of Autoimmune Disease and Inflammation by Regulating the Activity of Different T Cell Subsets	PLoS ONE	Liqun Luo, Gefeng Zhu et al.	96
14	PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation	Cancer Immunology Research	Nemanja Rodić, Robert A. Anders et al.	42
15	Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy breakdown →	Clinical Cancer Research	Janis M. Taube, Alison Klein et al.	1873
16	PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment	Journal of Neuro-Oncology	Dimitrios Mathios, Jacob Ruzevick et al.	60
17	B7-H2 Is a Costimulatory Ligand for CD28 in Human	Immunity	Sheng Yao, Yuwen Zhu et al.	118
18	Potential Role of Decoy B7-H4 in the Pathogenesis of Rheumatoid Arthritis: A Mouse Model Informed by Clinical Data	PLoS Medicine	Takeshi Azuma, Gefeng Zhu et al.	59
19	Leucocyte‐associated immunoglobulin‐like receptor‐1 is an inhibitory regulator of contact hypersensitivity	Immunology	Ryusuke Omiya, Fumihiko Tsushima et al.	16
20	B7-H4–deficient mice display augmented neutrophil-mediated innate immunity	Blood	Gefeng Zhu, Mathew M. Augustine et al.	68

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact